This open-label phase I study enrolled patients 18 years or older with newly diagnosed DLBCL. The first cohort (n = 6) received intravenous rituximab plus CHOP. This cohort received sqR for subsequent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results